Since the development of “liquid-based cytology” (LBC) in the mid-1990’s the clinical application and usage of LBC technology in a wide variety of clinical specimen has exploded. It has also allowed various molecular methods such as FISH, CISH and even classical IHC to be applied using a variety of markers in a variety of samples.
Whether it’s looking at her2 receptor in a breast FNA for guidance on chemotherapy or looking for aneuploidy in a urine sample screening for bladder cancer. Fifteen years of comprehensive publications document the clinical value to switching to LBC from classical smear or cytospin approaches.
But not all LBC systems are alike! The first generation systems were designed and targeted at cervical screening. Also these systems were designed to screen healthy asymptomatic women which is not the symptomatic populations screened in many parts of the world. This can result in increased repeat rates and perhaps the need to re-collect; costing the lab and patient money! Liqui-PREPTM is also molecular friendly, i.e. HPV
When processing samples with small volumes, like FNA or CSF, these automated system don’t process the entire sample and you can loose cells due to manipulation (i.e filters, funnels). Liqui-PREPTM is the only system which can be used across a broad mix of clinical samples providing a true cytology system approach.
The first LBC systems were designed for western cervical screening that then tried to process other clinical samples. Liqui-PREPTM is the first chemistry approach which can be used independent of the sample quality and volume. Symptomatic cervical samples can be processed without pretreatment or the need to be repeated due to clogged filters. Liqui-PREPTM can also be used to process a BAL, pleural fluid and urine samples with the same outcome, clean clear fields of vision with high cellularity